ABX · Abacus Global Management, Inc.
$8.27
-0.01 (-0.06%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$804.83M
Shares
97.79M
Volume · Oct 5
172.15K
Avg daily vol (3M)
610.16K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.27
Open$8.05
Day$8.05–8.35
52W close$5.02–12.00
Avg vol 30d581K
Short int4.8M · 4.9% float · 13.2d
Short vol54%
Last earningsAug 6, 2026
DataSep 2020–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 10, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$267.28M
Trailing 12 months
Net income (TTM)
$27.44M
Trailing 12 months
Revenue growth YoY
+29.9%
Year over year
Operating margin
31.8%
Trailing 12 months
P / E (TTM)
30.6
Trailing earnings · reciprocal yield 3.3%
FCF yield
11.1%
TTM · current market cap
Return on invested capital
7.0%
Trailing 12 months
Net cash
−$307.22M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.1%
Year over year · more shares
Price change (1Y)
+44.3%
Trailing year
Short interest
4.9%
Latest settlement · 13.2 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Abacus reported record Q2 revenue of $73.0M (+30% YoY) and adjusted EPS of $0.28, beating its guidance, and raised its Q3 adjusted EPS outlook to $0.26–$0.28 while reiterating full-year guidance of $1.00–$1.05. Longevity fund inflows of $544.2M in 1H26 surpassed the $500M target, the company launched its first registered interval fund (ABXGX), and GAAP net income declined 63% YoY due to acquisition-related and growth expenses.
Bullish
- + Record Q2 revenue of $73.0M, up 30% YoY, driven by Life Solutions growth of 38.3%.
- + Longevity funds raised $544.2M in 1H26, surpassing the $500M target and approaching the ~$604M raised in all of 2025.
- + Launched the ABX Longevity Growth and Income Fund (ABXGX), the first registered interval fund for the longevity asset class, opening access to individual investors.
- + Q3 guidance implies adjusted EPS up to 17% YoY at $0.26–$0.28, and management is targeting the top end of the reiterated full-year range.
Bearish
- − Asset management revenue declined YoY, driven by ETF AUM declines from market conditions and outflows.
- − Full-year adjusted EPS guidance of $1.00–$1.05 was reiterated rather than raised, even after a Q2 beat and higher Q3 outlook.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Research
our published analysis of this company
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
−11%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
47%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−15%
trailing
6-month return
−3%
trailing
YTD return
−3%
this year
Relative strength
−16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +39 funds added
Insider flow
Distributing
Net -$4.0M over 90 days · 100% sells
Short interest
Falling
4.91% of float · ▼ -1.4% MoM · 13.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
149 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+110%
Y/Y
Gross margin
88%
contracting
EPS growth
+206%
Y/Y
Free cash flow
$-26.6M
Valuation
P/E 30.5
rich
Buyback
$100.0M
authorized
Balance sheet
$367.7M
net debt
Quant / Vol
risk profile
Volatility
58%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
FY26
Adjusted net income (Gross)
Non-GAAP
Initiated
$100M – $106M
3Q26
Adjusted EPS (Gross)
Non-GAAP
Initiated
$0.26 – $0.28
Adjusted net income (Gross)
Non-GAAP
Initiated
$26M – $28M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
47%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $9 › 200d $9 — 50d above 200d
Institutional flow
Accumulating
+13% holders QoQ · +39 funds added
Insider flow
Distributing
Net -$4.0M over 90 days · 100% sells
Short interest
Falling
4.91% of float · ▼ -1.4% MoM · 13.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
149 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $8 · 47%
Range high $12
vs 200-day avg -10%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Average management fee on ETF Funds | 0.45% | Three Months Ended June 30, 2026 filing | — |
| Average management fee on Longevity Funds | 1.05% | Three Months Ended June 30, 2026 filing | — |
| Holding period on existing policies (in days) | 153 | Three Months Ended June 30, 2026 filing | — |
| Holding period on sold policies (in days) | 230 | Three Months Ended June 30, 2026 filing | — |
| Number of external counter parties that purchased policies | 6 | Three Months Ended June 30, 2026 filing | — |
| Number of policy originations to subsidiaries eliminated in consolidation | 138 | Three Months Ended June 30, 2026 filing | — |
| Policies bought | 288 | Three Months Ended June 30, 2026 filing | — |
| Policies bought from related parties | 8 | Three Months Ended June 30, 2026 filing | — |
| Policies matured | 19 | Three Months Ended June 30, 2026 filing | — |
| Policies originated for external investors | 44 | Three Months Ended June 30, 2026 filing | — |
| Policies sold | 300 | Three Months Ended June 30, 2026 filing | — |
| Policies sold to related parties | 278 | Three Months Ended June 30, 2026 filing | — |
| Total lifetime realized gains from maturities, net of lifetime premiums paid | $19,268,981 | Three Months Ended June 30, 2026 filing | — |
| Total lifetime realized gains, net of lifetime premiums paid | $62,032,077 | Three Months Ended June 30, 2026 filing | — |
| Turnover ratio | 2% | Three Months Ended June 30, 2026 filing | — |
| Weighted average realized gain on policies sold | 25.2% | Three Months Ended June 30, 2026 filing | — |
| Adjusted Annualized ROE non-GAAP | 22% | Six Months Ended June 30, 2026 | — |
| Adjusted Annualized ROIC non-GAAP | 20% | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | $72,596,972 | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA Margin non-GAAP | 54.8% | Six Months Ended June 30, 2026 | — |
| Adjusted EPS (Gross) non-GAAP | $0.28 | 2Q26 | — |
| Adjusted EPS - Basic non-GAAP | $0.41 | Six Months Ended June 30, 2026 | — |
| Adjusted EPS - Diluted non-GAAP | $0.4 | Six Months Ended June 30, 2026 | — |
| Adjusted Net Income non-GAAP | $39,497,137 | Six Months Ended June 30, 2026 | — |
| Adjusted net income (Gross) non-GAAP | 27.1M | 2Q26 | — |
| Annualized ROE non-GAAP | 25% | 2Q26 | — |
| Annualized ROIC non-GAAP | 23% | 2Q26 | — |
| Average realized gain | 25% | 2Q26 | — |
| Longevity funds capital inflows | 256.1M | 2Q26 | — |
| Longevity funds new capital raised | 544.2M | first half of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Insurance - Life — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABX
this stock
Abacus Global Management, Inc.
|
$804.83M | -3.3% | +110.2% | 30.5 | 4.9% |
|
CILJF
China Life Insurance Co Ltd
|
$107.41B | +4.3% | — | — | 0.0% |
|
MFC
Manulife Financial Corp
|
$72.67B | +18.3% | — | — | 0.5% |
|
MET
Metlife Inc
|
$62.09B | +19.6% | +8.6% | 18.7 | 1.9% |
|
GWLIF
Great-West Lifeco Inc.
|
$59.05B | +27.7% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABX | -0.2% | -15.2% | -3.4% | +2.6% | -3.3% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | 0.0% | -14.7% | -15.6% | +1.7% | -16.1% |
Capital returns
Buyback program
· as of Aug 13, 2026
Authorized
$100.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.